quinazolines has been researched along with Mesothelioma in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.82) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 29 (52.73) | 29.6817 |
| 2010's | 24 (43.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, W; Brankovic, J; Cufer, T; Dome, B; Grasl-Kraupp, B; Grusch, M; Gschwandtner, E; Hegedus, B; Hoda, MA; Kern, I; Klepetko, W; Klikovits, T; Laszlo, V; Mohorcic, K; Peter-Vörösmarty, B; Pirker, C; Rozman, A; Schelch, K; Sinn, K; Vlacic, G | 1 |
| Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II | 1 |
| Cherubini, C; Drudi, F; Fantini, M; Lazzari-Agli, L; Papi, M; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A | 1 |
| Box-Noriega, B; Fossella, FV; Gadgeel, S; Gandara, DR; Heymach, JV; Hueftle, JG; Kelly, K; Lu, C; Miao, J; Redman, MW; Tsao, AS; Velasco, MR; Vogelzang, NJ; Wistuba, II | 1 |
| Hejduk, K; Pochop, L | 1 |
| Nguyen, DM; Xin, HW; Yang, JH | 1 |
| Beuschel, SL; Hillegass, JM; MacPherson, MB; Macura, SL; Miller, JM; Mossman, BT; Perkins, TN; Sayan, M; Shukla, A; Thompson, JK | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Fidias, P; Jackman, DM; Jänne, PA; Johnson, BE; Kindler, HL; Lucca, J; Morse, LK; Ostler, PA; Salgia, R; Yeap, BY | 1 |
| Gatzemeier, U; Heigener, DF; Reck, M | 1 |
| Anraku, M; Bezjak, A; Burkes, R; Cho, BC; de Perrot, M; Feld, R; Johnston, MR; Keshavjee, S; Leighl, N; Roberts, H; Tsao, MS | 1 |
| De Vincenzo, F; Santoro, A; Simonelli, M; Zucali, PA | 1 |
| Ikeda, S; Suzuki, K; Takabe, K | 1 |
| Bajetto, A; Barbieri, F; Corte, G; Favoni, RE; Florio, T; Gatti, M; Gaudino, G; Lo Casto, M; Mutti, L; Paleari, L; Pattarozzi, A; Porcile, C | 1 |
| Baldi, A; Canino, C; Cardillo, I; Galati, R; Sacchi, A; Stoppoloni, D; Verdina, A | 1 |
| Baldi, A; Biroccio, A; Crispi, S; D'Angelo, C; Fagliarone, C; Galati, R; Sacchi, A; Verdina, A; Vincenzi, B | 1 |
| Carreau, JH; Foster, JM; Gatalica, Z; Govindarajan, V; Loggie, BW; Nath, SK; Radhakrishna, U; Sharma, P | 1 |
| Bellini, P; Favoni, RE; Harvey, BJ; Manente, AG; Moro, L; Mutti, L; Pinton, G; Thomas, W | 1 |
| Goto, H; Li, Q; Nakataki, E; Nishioka, Y; Ogino, H; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yano, S | 1 |
| Bueno, R; Corson, JM; Fletcher, JA; Flynn, DL; Hubert, C; Ou, WB; Sugarbaker, DJ | 1 |
| Dhalluin, X; Scherpereel, A | 1 |
| Paracha, N; Scott, DA; Thatcher, N; Woods, B | 1 |
| Chansky, K; Dasilva, MA; Gadgeel, SM; Gandara, DR; Garland, LL; Redman, M; Tsao, AS; Verschraegen, CF; Wozniak, AJ | 1 |
| Alecci, C; Assaraf, YG; Destro, A; Giancola, F; Gianoncelli, L; Giovannetti, E; Leon, LG; Lorenzi, E; Peters, GJ; Roncalli, M; Santoro, A; Smid, K; Zucali, PA | 1 |
| Surmont, VF; van Meerbeeck, JP | 1 |
| Grosso, F; Scagliotti, GV | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Agamah, E; Campbell, NP; Gandara, DR; Gitlitz, BJ; Kindler, HL; Koczywas, M; Kunnavakkam, R; Leighl, N; Stadler, WM; Thomas, SP; Vincent, MD; Vokes, EE | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Barthélemy, P; Daniel, C; Doubre, H; Fandi, A; Fizazi, K; Le Chevalier, T; Riviere, A; Robert, L; Ruffié, P; Viala, J | 1 |
| Ruffié, P | 1 |
| Ardizzoni, A; Baas, P; Debruyne, C; Giaccone, G; Grossi, F; Legrand, C; Monetti, F; Nackaerts, K; Numico, G; Smid-Geirnaerdt, MJ; van de Vijver, M; Van Marck, E; van Zandwijk, N | 1 |
| Vogelzang, NJ | 1 |
| Klabatsa, A; Steele, JP | 1 |
| Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D | 1 |
| Alleva, AM; Cole, GW; Maxhimer, JB; Nguyen, DM; Reddy, RM; Schrump, DS; Zuo, J | 1 |
| Bonomi, L; Imarisio, I; Mutti, L; Paglino, C; Porta, C; Sartore-Bianchi, A; Zimatore, M | 1 |
| Civiello, G; Janne, PA; Johnson, BE; Mukohara, T | 1 |
| Cortese, JF; Eliason, JF; Everson, RB; Gowda, AL; Pass, HI; Wali, A | 1 |
| Bottomley, A; Debruyne, C; Gaafar, R; Giaccone, G; Legrand, C; Manegold, C; Van Klaveren, RJ; Van Marck, EA; van Meerbeeck, JP; Vincent, M | 1 |
| Bottomley, A; Burgers, S; Coens, C; Gaafa, R; Gaafar, R; Giaccone, G; Legrand, C; Manegold, C; Van Meerbeeck, J; Vincent, M | 1 |
| Garcia-Carbonero, R; Paz-Ares, L | 1 |
| Aelony, Y | 1 |
| Albert, JM; Cao, C; Gi, YJ; Kim, KW; Ling, G; Lu, B; Mutter, RW; Shinohara, ET; Subhawong, TK; Willey, CD | 1 |
| Davies, AM; Ellis, P; Evans, WK; Haynes, AE; Lloyd, NS | 1 |
| Altomare, DA; Borden, EC; Gandara, DR; Garland, LL; Klein-Szanto, AJ; Nagle, RB; Rankin, C; Rivkin, SE; Scott, KM; Testa, JR | 1 |
| Burkitt, V | 1 |
| Bottomley, A; Burgers, S; Coens, C; Efficace, F; Gaafar, R; Legrand, C; Manegold, C; van Meerbeeck, JP; Vincent, M | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S | 1 |
| Armand, JP; Evans, TR; Seymour, L | 1 |
| Armand, J; Bedin, A; Caliandro, R; Cvitkovic, E; Daniel, C; Doubre, H; Fandi, A; Fizazi, K; Le Chevalier, T; Rodier, J; Ruffié, P; Soulié, P; Trandafir, L; Viala, J | 1 |
| Fizazi, K; John, WJ; Vogelzang, NJ | 1 |
| Cervantes, A; Cunningham, D; Glimelius, B; Maroun, J; Van Cutsem, E | 1 |
| Cantwell, BM; Earnshaw, M; Harris, AL | 1 |
15 review(s) available for quinazolines and Mesothelioma
| Article | Year |
|---|---|
Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Network Meta-Analysis; Pemetrexed; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome | 2017 |
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines | 2019 |
[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Glutamates; Guanine; Humans; Mesothelioma; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Thiophenes | 2008 |
Future developments in the management of malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Drug Delivery Systems; Forecasting; Glutamates; Guanine; Humans; Mesothelioma; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Quinazolines; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Thiophenes; Thoracic Surgical Procedures; Vinblastine; Vinorelbine | 2009 |
Antiangiogenic therapies for malignant pleural mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Humans; Mesothelioma; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Phenylurea Compounds; Piperidines; Pleural Effusion, Malignant; Pleural Neoplasms; Quinazolines; Quinolines; Thoracic Cavity; Vascular Endothelial Growth Factors | 2011 |
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mesothelioma; Pleural Neoplasms; Quinazolines; Ribonucleases; Thalidomide | 2011 |
Raltitrexed in mesothelioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Humans; Mesothelioma; Pleural Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2011 |
Systemic treatment of malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pleura; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome | 2012 |
Emerging insights into the biology and therapy of malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Chemotherapy options and new advances in malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Palliative Care; Pemetrexed; Pleural Neoplasms; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2005 |
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Peritoneal Neoplasms; Quinazolines; Thiophenes; Vinblastine; Vinorelbine | 2006 |
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Neoplasm Invasiveness; Patient Selection; Pemetrexed; Pleural Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Treatment Outcome | 2006 |
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Mesothelioma; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Folic Acid Antagonists; Glutamates; Guanine; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Pleural Neoplasms; Quinazolines; Thiophenes | 2002 |
Raltitrexed: current clinical status and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2002 |
15 trial(s) available for quinazolines and Mesothelioma
| Article | Year |
|---|---|
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Quinazolines | 2017 |
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Progression-Free Survival; Quinazolines | 2019 |
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quinazolines; Survival Rate | 2008 |
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate | 2011 |
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Mesothelioma; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2003 |
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome | 2005 |
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer In
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quality of Life; Quinazolines; Thiophenes; Treatment Outcome | 2006 |
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2007 |
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural
Topics: Antineoplastic Agents; Cisplatin; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Prognosis; Prospective Studies; Quality of Life; Quinazolines; Self-Assessment; Thiophenes | 2007 |
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Digestive System Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 1999 |
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.
Topics: Adult; Drug Evaluation; Folic Acid; Folic Acid Antagonists; Humans; Mesothelioma; Middle Aged; Quinazolines | 1986 |
25 other study(ies) available for quinazolines and Mesothelioma
| Article | Year |
|---|---|
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Topics: Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Survival Analysis | 2019 |
[Report from a small registry-permetrexed, tarceva and yondelis].
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Mesothelioma; Pancreatic Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Sarcoma | 2013 |
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
Topics: Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Quinazolines; Signal Transduction | 2013 |
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cyclic AMP Response Element-Binding Protein; Doxorubicin; Drug Synergism; Humans; MAP Kinase Signaling System; Mesothelioma; Mitogen-Activated Protein Kinase 7; Neoplasms, Connective Tissue; Phosphorylation; Piperidines; Quinazolines; RNA, Small Interfering; Sarcoma | 2014 |
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Thiophenes; Vinblastine; Vinorelbine | 2009 |
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Quinazolines | 2009 |
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cross-Linking Reagents; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Mesothelioma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Multimerization; Quinazolines; Tumor Cells, Cultured | 2010 |
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lactones; Mesothelioma; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfones | 2010 |
Antiproliferative effect of Aurora kinase targeting in mesothelioma.
Topics: Aurora Kinase A; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Mesothelioma; Microarray Analysis; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Quinazolines | 2010 |
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Topics: DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesothelioma; Mutation; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
Topics: Blotting, Western; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor beta; Gefitinib; Humans; Immunoprecipitation; Mesothelioma; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference | 2010 |
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Interactions; Enzyme Activation; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Mesothelioma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Sulfones | 2011 |
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Glutamates; Guanine; Health Care Costs; Humans; Mesothelioma; Pemetrexed; Pleural Neoplasms; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2012 |
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Topics: Apoptosis; Blotting, Western; Carboplatin; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Pemetrexed; Phosphorylation; Piperidines; Pleural Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
[New therapeutic options for mesothelioma].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; France; Gemcitabine; Humans; Mesothelioma; Mitomycin; Neoplasm Staging; Patient Selection; Pneumonectomy; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Thiophenes; Treatment Outcome; Vindesine | 2002 |
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Cocarcinogenesis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation, Neoplastic; Humans; Laminin; Mesothelioma; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Pleural Neoplasms; Proteoglycans; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A | 2005 |
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mesothelioma; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.
Topics: Cisplatin; Clinical Trials as Topic; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pleural Neoplasms; Pleurodesis; Quality of Life; Quinazolines; Talc; Thiophenes; Treatment Outcome | 2006 |
Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
Topics: Aurora Kinase B; Aurora Kinases; Benzamides; Caspase 3; Cell Survival; G2 Phase; Histones; Humans; Inhibitor of Apoptosis Proteins; Mesothelioma; Microtubule-Associated Proteins; Mitosis; Neoplasm Proteins; Oligonucleotides, Antisense; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Radiation Tolerance; Survivin; Up-Regulation | 2007 |
In Australia, patients and government at odds over mesothelioma treatment costs.
Topics: Abdominal Neoplasms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Australia; Canada; Carcinogens; Cisplatin; Cost-Benefit Analysis; Environmental Exposure; Glutamates; Government; Guanine; Health Care Costs; Humans; Incidence; Lobbying; Lung Neoplasms; Mesothelioma; Patient Advocacy; Pemetrexed; Quinazolines; Thiophenes; Thoracic Neoplasms; United Kingdom | 2007 |
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2008 |